Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24

Glenmark Pharmaceuticals receives ANDA approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg

Glenmark Pharma is first to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-morbidities

Glenmark Pharmaceuticals receives ANDA approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg

Cosmo and Glenmark announce the signing of Distribution and License Agreements for Winlevi® in Europe and South Africa

Glenmark Pharma announces Proposed Divestment of Majority Stake in Glenmark Life Sciences

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

Glenmark Pharma reports revenue growth of 22.5%, EBITDA growth of 46.2% YoY for Q1 FY 2023-24

Glenmark Pharmaceuticals receives ANDA approval for Saxagliptin Tablets, 2.5 mg and 5 mg

Glenmark Pharma reports revenue growth of 11.7% YoY Q4; 5.6% for the full year FY 2022-23

Glenmark Pharmaceuticals is Great Place To Work® Certified™ in India

Glenmark Pharmaceuticals receives ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg

Glenmark receives acceptance from U.S. FDA on its IND application for GRC 54276 to proceed with a Phase 1/2, first-in-human clinical study of the molecule for the treatment of patients with advanced solid tumors and lymphomas

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg

Glenmark and Cediprof Announce Exclusive Distribution Agreement in the United States for U.S. FDA Approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

Glenmark Pharma reports revenue growth of 9.2% and PAT growth of 21.3% YoY for Q3 FY 2022-23

The Glenmark Nutrition Awards 2023 recognized NGOs and Institutions tackling Malnutrition in Mothers and Children

Glenmark launches AKYNZEO® I.V. in India – First Fixed I.V. Antiemetic Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting

Heart failure treatment becomes more affordable with Glenmark launching the Sacubitril + Valsartan tablets in India

Glenmark Pharmaceuticals launches Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials